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Abstract: Despite effective treatment for those living with Human Immunodeficiency Virus (HIV),
there are still two million new infections each year. Protein-based HIV entry inhibitors, being highly
effective and specific, could be used to protect people from initial infection. One of the most promising
of these for clinical use is 5P12-RANTES, a variant of the chemokine RANTES/CCL5. The N-terminal
amino acid of 5P12-RANTES is glutamine (Gln; called Q0), a residue that is prone to spontaneous
cyclization when at the N-terminus of a protein. It is not known how this cyclization affects the
potency of the inhibitor or whether cyclization is necessary for the function of the protein, although
the N-terminal region of RANTES has been shown to be critical for receptor interactions, with even
small changes having a large effect. We have studied the kinetics of cyclization of 5P12-RANTES as
well as N-terminal variations of the protein that either produce an identical cyclized terminus (Glu0)
or that cannot similarly cyclize (Asn0, Phe0, Ile0, and Leu0). We find that the half life for N-terminal
cyclization of Gln is roughly 20 h at pH 7.3 at 37 ◦C. However, our results show that cyclization is not
necessary for the potency of this protein and that several replacement terminal amino acids produce
nearly-equally potent HIV inhibitors while remaining CC chemokine receptor 5 (CCR5) antagonists.
This work has ramifications for the production of active 5P12-RANTES for use in the clinic, while
also opening the possibility of developing other inhibitors by varying the N-terminus of the protein.
Keywords: 5P12-RANTES; Chemokine (C-C Motif) Ligand 5 (CCL5); HIV entry inhibition;
N-terminal cyclization; chemokine
1. Introduction
HIV, the virus that causes acquired immune deficiency syndrome (AIDS), infects about 2 million
people each year, mostly throughout the developing world [1]. While effective treatments are available,
particularly in economically advanced countries, there is no cure, and prevention remains a critical
issue. A major strategy to prevent HIV infection is the development of microbicides, substances that
could be used topically to prevent the sexual spread of HIV. Ideally, a microbicide would be active
and remain functional in both the vaginal compartment (pH 4.0–4.5) [2] and the rectal compartment
(pH 7) [3].
One of the most promising proteins under consideration for use as a microbicide is 5P12-RANTES.
This protein was developed using random mutagenesis at the N-terminus of the chemokine RANTES
(also called Chemokine (C-C Motif) Ligand 5 (CCL5)) [4], itself a weak HIV inhibitor. 5P12-RANTES
binds tightly to the chemokine receptor CCR5 (CC chemokine receptor 5), which is the major
co-receptor used by HIV to gain entry to the cell during initial infection [5,6]. 5P12-RANTES has also
been shown to be stable at biological temperatures and in the presence of relevant bodily fluids [7],
and it was fully protective as a topical microbicide when tested in macaques [8]. More recently, it has
been reported as being under clinical development [9].
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The N-terminal region of chemokines are known to be critical for function, with slight
alterations or truncations known to cause significant differences in their interaction with their
respective receptors [10–13]. For example, the simple addition of an N-terminal methionine caused
RANTES/CCL5 to act as a CCR5 antagonist rather than an agonist [10], and truncation of the
N-terminal residues of chemokines likewise led to proteins with the ability to bind but not activate
CCR5 [12,14]. In developing chemokines as HIV inhibitors, chemically modifying the N-terminus of
RANTES was found to be particularly effective. For example, one potent analog was AOP-RANTES,
in which an organic extension replaced the first residue of RANTES [15]. This modified protein
was not only a potent HIV inhibitor, but it also prevented chemotaxis of human monocytes; this
is a valuable property because it is important to avoid bringing immune cells to a site where they
could potentially be infected with HIV [16]. Researchers then used this design as a scaffold and
tested various synthetic modifications to the N-terminus, resulting in the discovery of the even more
potent PSC-RANTES; both AOP-RANTES and PSC-RANTES induce internalization of the CCR5
receptor [17,18]. However, neither of these variants could be produced recombinantly. To circumvent
this issue, Hartley et al. developed a random mutagenesis/phage display technique with changes to
the N-terminal resides of RANTES that led first to the production of P2-RANTES [13] and then to the
discovery of 5P12-RANTES [4]. The mutations that produced 5P12-RANTES were focused on just the
first ten amino acids in RANTES and showed over two orders of magnitude variation in inhibitory
potency [4].
Interestingly, 5P12-RANTES as well as the other resultant inhibitors carried forward from the
study, such as 5P14-RANTES and 6P4-RANTES, have a glutamine as the first amino acid (termed
“Q0” because this is an additional amino acid added to the wild type RANTES sequence). N-terminal
glutamines are able to chemically cyclize [19–21] (Figure 1), leading to possible heterogeneity in the
protein product with two forms (cyclized and uncyclized) that are significantly different in charge and
other chemical properties. This has also been a topic of significance in the development of antibodies
as therapeutics, where N-terminal Gln and Glu are both common [19,22–24]. The increasing use of
antibodies as therapeutics has led to several reports about the importance of cyclization of both Gln
and Glu at the N-terminus of these and other clinically-relevant proteins [20,23–25].
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Figure 1. Cyclization reactions of N-terminal glutamine and glutamate residues in a polypeptide
chain. Conditions such as pH are important factors in the rate of cyclization; low pH leads to a higher
proportion of a good leaving group, while high pH leads to better nucleophilicity in the attacking
amino group [22,26].
While it has been recognized that 5P12-RANTES is likely to undergo N-terminal cyclization,
the functional impact of this modification at such a critical region of the protein, as well as the details
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of the kinetics of cyclization, have not yet been reported [4,9,27]. Such information is critical both
from the standpoint of understanding the mechanism of HIV inhibition and from the standpoint of
identifying all forms of a molecule that may enter the clinic.
Here, we report a study on the N-terminal cyclization of 5P12-RANTES, including the effect of
cyclization on CCR5 receptor function and HIV inhibition in two representative strains, as well as the
rate of cyclization under various conditions. We also show the effect of mutating the N-terminal “Q0”
to other amino acids, such as the residue glutamate, which cyclizes to form an identical molecule to
“wild type” cyclized 5P12-RANTES.
2. Results
2.1. 5P12-RANTES N-Terminal Cyclization
15N labeled 5P12-RANTES was produced from E. coli with an N-terminal fusion partner to
disallow N-terminal cyclization of Q0 for most of the purification process. Cleavage of the fusion tag
by enterokinase was carried out at pH 7.4 at 4 ◦C followed by reversed-phase chromatography and
lyophilization of the pure protein so that it could be stored as dry powder to inhibit cyclization.
The purified 5P12-RANTES was solubilized at pH 2.8 for Nuclear Magnetic Resonance (NMR)
spectroscopy, where it was observed that less than 5% of the protein had undergone N-terminal
cyclization during the purification process (Figure 2).
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Figure 2. Heteronuclear single quantum coherence (HSQC) nuclear magnetic resonance (NMR)
spectrum of 15N-labeled 5P12-RANTES directly after dissolution in pH 2.8 20 mM sodium phosphate
buffer at 25 ◦C. Little or no cyclization is observed at this time. Cyclization of Q0 results in a shift of
the G1 peak (labeled, grey arrows; cyclized position circled) which can be used to quantify the amount
of cyclized 5P12-RANTES in solution. Cyclization also results in loss of Q0 side chain amide peaks
(black arrows, circled) and appearance of cyclized Q0 lactam peak (black arrow, circle). Chemical
shift assignments from Wiktor et al. [28]; no assignments are shown for region near E66, where these
authors used a variant. Also not shown are side chain assignments for W57 and Asn/Gln (except for
the relevant N-terminal side chain amide). Percent cyclization was determined by peak height at lower
contour level than shown.
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The cyclization rate of the N-terminal Gln of 5P12-RANTES at 37 ◦C was monitored by NMR at
pH 7.3 and at pH 2.8 as shown in Figure 3B. A clear indication of cyclization at the N-terminal “Q0”
position is the peak position of the backbone amide of glycine 1. This peak shows a clear shift from
8.7 ppm (1H) and 112.5 ppm (15N) to 8.4 ppm (1H) and 109.5 ppm (15N) as its neighboring side chain
cyclizes [9] (Figures 2 and 3A). Concomitantly, the lactam peak of the cyclized pyroglutamate (derived
from Q0) is observed to grow in at 7.9 ppm (1H) and 125.5 ppm (15N) upon cyclization. At pH 7.3
these peaks are not discernable in an HSQC spectrum, likely due to faster amide exchange. Therefore
NMR analysis for the pH 7.3 incubation was carried out at pH 2.8.
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As shown in Figure 3B, Q0 cyclization of 5P12-RANTES at pH 7.3 (37 ◦C) exhibits a half life of
about 20 h. When cyclization is measured with constant incubation at pH 2.8 (37 ◦C), the half life is
about 33 h, with cyclization essentially complete at 120 h.
2.2. 5P12-Q0E Also Cyclizes to Produce Mature 5P12-RANTES
To further investigate the properties of the N-terminus of 5P12-RANTES, we produced
5P12-RANTES-Q0E, in whic the Gln is replaced by the amino acid Glutamate, which is also capable
of cyclizing when placed at the amino terminus of a pr tein. While the cyclization i expected to
be slower due to the poor leaving group o the Glu side chain, the product of cycl zation should
identical to cyclized Q0. This variant all ws further tudy of cyclization and also provides an alternat
route to the presumed mature p oduct i.e., fully cyclize 5P12-RANTES cont ining a pyroglutamate at
the N-terminus.
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Isotopically labeled 15N 5P12-RANTES-Q0E was produced with an N-terminal fusion protein
to disallow cyclization until cleavage near the end of purification, in a similar manner as with
5P12-RANTES. Initial solubilization of purified, lyophilized protein followed by NMR revealed
that less than 4% of this protein was cyclized during purification (Figure 4A). Incubation of 15N
5P12-RANTES-Q0E was carried out at pH 7.3 and pH 2.8 and monitored by NMR as described above.
As shown in Figure 4B, the reaction to produce N-terminal pyroglutamate takes many days, with
a half-life of greater than 150 days at pH 7.3 and a half-life of about 60 days at pH 2.8. This faster
cyclization at low pH is expected due to improvement of the leaving group upon protonation. When
cyclization is complete, the spectrum is identical to cyclized “wild type” 5P12-RANTES as expected
(Figure S1).
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is identical to that of 5P12-RANTES except for a slight G1 shift (grey arrows) and a loss of two side
chain amide peaks corresponding to the Gln-0 NH2 group and no cyclized peak (black arrow, circled,
lower right). Cyclization results in a shift of the G1 residue (labeled) which can be used to quantify
the amount of cyclized 5P12-RANTES-Q0E in solution. Spectrum was measured in 20 mM sodium
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than shown. (B) Cyclization over time of 5P12-RANTES-Q0E in pH = 7.3 and pH = 2.8, incubated at
37 ◦C. Spectrum at the 150 day time point shows folded protein, with some degradation (Figure S2).
2.3. High Potency HIV Inhibition Does Not Require N-terminal Cyclization or N-Terminal Glutamine
To determine the relative importance of N-terminal cyclization on the anti-HIV potency of
5P12-RANTES, singl ound viral assays were carried out using two representative strains of HIV.
Since these assays necessari y use mammalian cells, conditions are constr ined to physiological pH
(pH 7.3). In these assa s, cells are liquot d into 96 well plates and allowed to divide overnight.
Various dilutions of inhibitor (freshly made from lyophilized powder and minimally cyclized) were
inc bated with t e cells for 30 min. Virus was then added and the cells incubated overnight. Medium
containing v rus and inhibitor were removed the following day as medi m was cha ged and cells
were allowed to grow an additional two days with fresh me ium. Infection mo itored with a
stand rd β-galactosidase rea out as described in Methods. The total time the inhibit r s in solution
and able to cyclize is 20 h at pH 7.3 in this assay.
As sh wn in Table 1, “immature” 5P12-RANTES that was essentially uncyclized at the start of the
assay gave an IC50 of 1.5 ± 0.10 nM for strain PVO.4 and 1.61 ± 0.12 nM for strain ZM53. Given he
length of the assay, it is estimated that roughly 50% of the immature 5P12-RANTES did cyclize during
course f t e assay. How ver, virus entry has been demonstrated o take place over the course of
minutes [29], so a signific nt amount of virus-cell interaction could be expected before the inhibi or
was ignifica tly cyclized. “Matured” 5P12-RANTES (that was incubated for 36 h, pH 2.8 at 50 ◦C to
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allow full cyclization prior to use in the HIV assay) showed essentially equal potency, with an IC50 of
1.27 ± 0.10 nM for PVO.4 and 1.46 ± 0.15 nM for ZM53.
Table 1. IC50 values of 5P12-RANTES variants (in nM) against a Clade B HIV viral strain (PVO.4) or
Clade C viral strain (ZM53) in single-round pseudoviral infection assays. Assays were performed in
triplicate and repeated three times.
IC50 Values of 5P12 Variants
5P12 Variant PVO.4 (nM) ZM53 (nM)
5P12-RANTES Uncyclized 1.51 ± 0.10 1.61 ± 0.12
5P12-RANTES Cyclized 1.27 ± 0.10 1.46 ± 0.15
5P12-RANTES-Q0E Uncyclized 6.30 ± 0.14 4.04 ± 0.29
5P12-RANTES-Q0E Cyclized 1.09 ± 0.06 1.23 ± 0.09
5P12-RANTES-Q0N 2.20 ± 0.33 1.31 ± 0.19
5P12-RANTES-Q0I 1.21 ± 0.24 1.43 ± 0.11
5P12-RANTES-Q0F 1.26 ± 0.19 1.84 ± 0.12
5P12-RANTES-Q0L 1.31 ± 0.12 1.45 ± 0.15
The mutant 5P12-Q0E showed somewhat poorer inhibition in its immature, uncyclized form, with
an IC50 of 6.30 ± 0.14 nM for PVO.4. This variant has a negatively charged glutamate at position 0,
a part of the protein that is presumed to interact with the receptor CCR5 in or near the hydrophobic
membrane of the cell [30]. Given the half-life of cyclization described above, it is expected that during
the assay, under 5% of this protein would be cyclized. When the matured, cyclized 5P12-Q0E (prepared
as described in Methods) was used in these inhibition assays, its potency was essentially identical to
wild type, cyclized 5P12-RANTES (Table 1), as expected for these two now-identical proteins.
As a control for uncyclized Q0 (“wild type”) 5P12-RANTES, we produced and purified 5P12-Q0N,
in which the Gln is replaced by Asn. This amino acid is identical to Gln but has a shorter side chain so
cannot similarly cyclize. As expected, the NMR spectrum of 15N 5P12-Q0N shows no indication of a
cyclized N-terminus (Figure S3A). In HIV inhibition assays, this protein shows high potency, with an
IC50 of 2.20 ± 0.33 nM against PVO.4 and 1.31 ± 0.19 against ZM53, essentially the same as for the
wild type (Q0) protein, indicating that the presence of a cyclized pyroglutamate is not necessary for
the anti-HIV activity of 5P12-RANTES.
Since both uncyclized and cyclized 5P12 variants were shown to be potent inhibitors of HIV,
we made other mutations at the Q0 position of the protein to determine the effect of changes at this
position on HIV inhibitory ability. For these experiments the Gln0 was changed to Phe, Ile, and Leu.
Each of these variants was expressed and shown to be folded by NMR (Figure S3B–D); none of these
side chains are expected to undergo significant chemical transformation upon incubation. As shown in
Table 1, each variant was highly potent and very similar in activity to 5P12-RANTES, with IC50 values
ranging from 1.21 ± 0.24 nM to 1.31 ± 0.13 nM (PVO.4) and 1.43 ± 0.11 nM to 1.84 ± 0.12 nM (ZM53).
2.4. The Effect of the N-Terminal Amino Acid and Its State of Cyclization on Activation of CC Chemokine
Receptor 5 (CCR5)
5P12-RANTES has been reported to be an antagonist of CCR5, not inducing calcium mobilization;
lack of calcium mobilization is a property that is favorable (and likely necessary) in the context of
therapeutic HIV inhibition. To determine whether the cyclization of Q0 or the placement of other amino
acids at the N-terminus affect activation of CCR5, calcium flux assays were carried out on Chinese
Hamster Ovary (CHO) cells expressing CCR5, Gα16, and apo-aequorin, a calcium-responsive protein.
As shown in Figure 5, neither N-terminally cyclized nor N-terminally uncyclized 5P12-RANTES
(i.e., having Q0) caused a calcium flux until concentrations reached 500 nM, while wild type
RANTES/CCL5 showed calcium release at low nM concentrations as expected. Further, the N-terminal
variants of 5P12-RANTES (-Q0E cyclized and uncyclized, -Q0N, -Q0I, -Q0F, -Q0L) also exhibited no
ability to cause the release of calcium until reaching 500 nM concentration (Figure 5). These results
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were further confirmed with a fluorescence assay using human HeLa-P5L cells, which showed similar
results (Table S1).Int. J. Mol. Sci. 2017, 18, 1575 7 of 15 
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induce downstream signaling or internalization of the CCR5 receptor. Therefore, this inhibitor can
inhibit HIV without activating the immune system or mediating an influx of immune cells (and by
virtue of being a CCR5 antagonist, may actually reduce immune activity).
5P12-RANTES has been shown to have many properties necessary for use as a topical microbicide,
including stability at elevated temperatures, a range of pH conditions, and within environments
containing bodily fluids [7,42]. This inhibitor demonstrated the ability to prevent infection in
macaques [8] and has shown effectiveness against many strains of HIV with little or no indication that
HIV is able to mutate to lose sensitivity to it [43]. Therefore, this protein is a top candidate for a clinical
HIV microbicide.
A critical issue for any protein moving to the clinic is a clear understanding of its function, as well
as characterization of any variation in its chemical or structural composition. For instance, antibodies
often have Glu or Gln as N-terminal residues, and the growing importance of antibodies as therapeutics
has led to the study of these residues’ propensity to cyclize [19,22–24]. 5P12-RANTES has an N-terminal
Gln (referred to as Q0), an amino acid that is known to cyclize when at this position in a protein [19,44],
leading to an extra cyclization step during clinical-grade production [27]. However, a detailed study of
the rate and functional effect of this cyclization in 5P12-RANTES has not been reported.
Wiktor et al. have provided NMR chemical shift assignments and the structure of a
non-aggregating variant of 5P12-RANTES [9,28]. This group estimated a half-life for Q0 cyclization
as approximately two days at pH 3.8, although the sample was refrigerated during part of this time,
since the primary goal of the work was not to study N-terminal cyclization but rather to investigate
the overall structure of the protein and its interactions with detergents.
We have shown here that the N-terminus of 5P12-RANTES cyclizes to form pyroglutamate with a
half-life of roughly 20 h at pH 7.3 and 33 h at pH 2.8 (37 ◦C). This indicates that the protein, if purified
without regard to cyclization, would still cyclize on the time scale of a typical HIV assay (20 h at
pH 7.3), leaving inconclusive whether high potency is reserved for only the cyclized form. However,
when Q0 is replaced with N, such cyclization is not observed, and this variant (5P12-Q0N) shows
essentially identical HIV-inhibitory ability as 5P12-RANTES, indicating that a cyclized N-terminus is
not important for the function of this inhibitor. Other hydrophobic N-terminal variants, -Q0I, -Q0F,
-Q0L, also show very high potency, nearly equivalent to 5P12-RANTES (Table 1).
To further investigate the importance of the cyclized form of 5P12-RANTES, we made 5P12-Q0E,
in which glutamate replaces glutamine at the N-terminus of the protein. Glutamate can also be
expected to cyclize and form the same pyroglutamate as is formed by glutamine (Figure 1), although a
poorer leaving group is expected to cause this reaction to be slower. Upon cyclization, this variant will
yield a product that is identical to cyclized 5P12-RANTES.
It was observed that at 37 ◦C, 5P12-Q0E cyclization occurs with a half-life of well over 150 days at
pH 7.3 (with still only 25% cyclization observed at 150 days) and roughly 60 days at pH 2.8. The fully
cyclized version of the variant (prepared by prolonged incubation at higher temperatures) was tested
against two strains of HIV and shown to be essentially identical in function to cyclized 5P12-RANTES
containing the original Q0. Interestingly, the uncyclized 5P12-Q0E also showed good inhibitory
properties despite the timescale of the assay not allowing significant cyclization and therefore leaving
a negatively charged Glu at the terminus of the protein throughout the assay (Table 1).
These results clarify the conditions necessary to cyclize 5P12-RANTES if it were to be used
clinically in a homogeneous form. They further show that not only is cyclization not necessary for
anti-HIV activity, but also that a variety of amino acids at the N-terminus would be expected to
provide protection against HIV infection. This allows a greater range of amino acid sequences as
potential inhibitors, which could lead to flexibility in determining which sequence most easily results
in production of the large amounts of protein required for clinical use.
In conclusion, 5P12-RANTES is a highly potent HIV inhibitor that could be used as a microbicide
to prevent HIV infection. However, chemical cyclization of its N-terminal glutamine causes this protein
to exist as a heterogeneous mixture when expressed recombinantly. We show that the protein is still a
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highly effective inhibitor of HIV in both its cyclized and uncyclized forms and have determined the
rate of cyclization under various conditions, with relevance both for the manufacture and clinical use
of this protein. We also show that several amino acids are suitable replacements for the N-terminal
glutamine if changes in the sequence are necessary or desirable.
4. Materials and Methods
4.1. Protein Purification
In brief, the following method was used (with the exception of wild type RANTES/CCL5, which
required some differences as noted): Plasmids were transformed into Escherichia coli BL21 (DE3)
(Novagen) competent cells and expressed in minimal media with 15NH4Cl as the sole nitrogen source.
Protein production was induced with the addition of isopropyl β-d-1-thiogalactopyranoside (IPTG)
and incubated with shaking at 22 ◦C for 20 h (wild type RANTES/CCL5 was induced with IPTG
followed by shaking at 37 ◦C for 6 h). The cell pellet was resuspended in 6 M guanidine hydrochloride,
200 mM NaCl, 10 mM benzamidine, and 50 mM Tris (pH 8.0) and was then disrupted by French press
and then centrifuged at 27,000× g for 1 h. The soluble portion was loaded onto a nickel chelating
column (Qiagen, Hilden, Germany) equilibrated with the resuspension buffer. Proteins were eluted
from the column using a pH gradient with 6 M guanidine hydrochloride, 200 mM NaCl, and 60 mM
NaOAc (pH 4) followed by addition of 10 mM β-mercaptoethanol with stirring for one hour at room
temperature. The proteins were then refolded by dropwise addition to 10× volume of refolding buffer
(550 mM L-Arginine Hydrochloride, 200 mM NaCl, 1 mM EDTA, 1 mM reduced glutathione (GSH),
0.1 mM oxidized glutathione (GSSG), 50 mM Tris, pH 8), and then allowed to stir overnight at 4 ◦C.
The solution was dialyzed twice into 4 liters 200 mM NaCl, 2 mM CaCl2, 20 m Tris, pH 7.4 buffer at
4 ◦C (into 4 L of 200 mM NaCl, 20 mM Tris pH 8 for wild type RANTES).
To cleave fusion tags from the purified protein, the samples were incubated for 24 h with 650 nM
of the protease enterokinase (5P12-RANTES-Q0E required 3 days at a 2 µM; 100 nM ULP-1/SUMO
protease was used to cleave wild type RANTES/CCL5; protease purification described below) The
protein solution was then centrifuged to remove precipitated material and added onto a second
nickel chelating column (Qiagen, Hilden, Germany), with unbound eluate (containing the cleaved
5P12-RANTES or its variants) being collected. (This second nickel column is not necessary for wild type
RANTES/CCL5 purification). The samples were then dialyzed and purified on a C4 reversed-phase
chromatography column (Vydac, Hesperia, CA, USA), using an acetonitrile gradient. Wild type
RANTES/CCL5 was also purified with the C4 column, allowing separation from the SUMO tag.
Overall, samples were near neutral pH for about a day during proteolytic cleavage (3 days for
5P12-Q0E due to slow cleavage) and a day for dialysis to prepare conditions for the C4 column, during
which time N-terminal cyclization was possible. However, dialysis was carried out at 4 ◦C to minimize
this reaction, and as noted in Results, little cyclization was observed after this point. The fractions were
analyzed on an SDS-PAGE gel to confirm purity and then lyophilized in a Labconco freeze-dry system.
N-terminally cyclized proteins used for functional assays (below) were prepared as follows:
purified and lyophilized 5P12-RANTES was incubated for 36 h at 50 ◦C in 20 mM sodium phosphate
buffer pH 2.8 to ensure 100% cyclization. 5P12-RANTES-Q0E was incubated for 50 days at 50 ◦C in
20 mM sodium phosphate buffer pH 2.8 to fully cyclize. Both samples were tested by NMR to confirm
structural integrity and full cyclization (Figure S1).
The proteases used in these purifications were produced and purified in our laboratory as briefly
described: Ubl-specific protease 1 or enterokinase protease were proteins were expressed in Luria
Broth (LB) medium using a pET-28b vector and the cells were collected and French pressed. The ULP1
protease from the supernatant was purified using a nickel chelating column [45]. The enterokinase was
found in the inclusion body and resuspended in 6 M guanidinium chloride buffer before being purified
using a nickel chelating column. Enterokinase was then dialyzed in buffer to allow for refolding and
tested for activity through self-cleavage of the fusion tag (manuscript in preparation).
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4.2. Obtaining Rates of 5P12-RANTES and 5P12-RANTES-Q0E Cyclization
Samples incubated at pH 2.8 were prepared by adding 15N-labeled lyophilized protein
(5P12-RANTES or 5P12-RANTES-Q0E) to 20 mM sodium phosphate buffer with 10% D2O and 5 µM
DSS, resulting in a final pH = 2.8. Samples were placed into Shigemi NMR tubes (Shigemi, Inc., Allison
Park, PA, USA) and incubated at 37 ◦C. NMR spectra were periodically measured at 37 ◦C for these
samples (see below).
Samples at pH = 7.3 (the same pH as the pseudoviral assay medium) were prepared by adding
15N-labeled lyophilized protein (5P12-RANTES or 5P12-RANTES-Q0E) to 5 mM Sodium Phosphate
buffer with 0.02% sodium azide with a final pH of pH 7.3. Proteins were incubated at 37 ◦C, and
samples were removed at selected time points, flash-frozen using liquid nitrogen, and lyophilized.
Samples were then dissolved in 20 mM Phosphate buffer, 5% D2O, and 5 µM DSS with a final pH = 2.8,
and then measured by NMR at 25 ◦C (see below). All measurements for the pH of protein samples
were taken with a micro electrode (Thermo Scientific/Orion).
4.3. NMR Spectroscopy
15N-labeled lyophilized proteins were added into 20 mM Sodium Phosphate buffer with 10%
D2O and 5 µM 2,2-dimethyl-2-silapentane-5-sulfonic acid (DSS), with a final pH = 2.8 for all samples.
Concentration of protein ranged from 30 uM to 80 uM. Sample preparation for cyclization time points
are further described above. All NMR data were acquired on a four-channel 600 MHz Bruker Avance
III spectrometer equipped with a GRASP II gradient accessory and a TCI cryoprobe with an actively
shielded Z-gradient coil. Spectra were measured at 25 ◦C or 37 ◦C. The chemical shift was referenced
relative to internal DSS [46]. The data were processed using NmrPipe [47] and analyzed using PIPP [48].
For HSQC spectra, sweep width = 8474.576 (1H) and 1766.784 Hz (15N), with 1280 points in 1H and
128 * (256 total) points in 15N.
4.4. Quantifying N-Terminal Cyclization
N-terminal cyclization of 5P12-RANTES or 5P12-RANTES-Q0E results in the appearance of an
N-terminal lactam peak “Gln0” (Figures 1 and 2), as well as a shift in the Gly1 backbone amide
peak. [9,28] (Figures 2 and 3A). Peak height comparison of the Gly1 amide when the N-terminus of
the protein is cyclized versus uncyclized was used to estimate the percent of the protein cyclized in
the sample as follows. NmrPipe was used to obtain peak heights for the Gly1 amide. The percent
cyclization was obtained by dividing the height of the Gly1 peak when the N-term was cyclized by
the sum of the heights of both cyclized and uncyclized Gly1 peaks in a spectrum. Similar values were
obtained when using the peak height of the cyclized Q0 peak to measure the cyclized amount. Using
peak volumes rather than height did not appreciably change the result.
4.5. Cell Lines and Viruses
HeLa-TZM-bl cells were obtained through the AIDS Research and Reference Reagent Program,
Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of
Health; the HeLa-TZM-bl cell line was from John C. Kappes, Xiaoyun Wu, and Tranzyme Inc. 293FT
cells were originally obtained from Invitrogen; CHO-K1 cells stably expressing CCR5, Gα16, and
apo-aequorin were a kind gift from Marc Parmentier from the Institute of Interdisciplinary Research of
the Free University of Brussels (ULB) Medical School, Brussels, Belgium. HeLa-P5L Cells (a cell line
stably expressing human receptor CD4 and CCR5) was a kind gift from M. Alizon (Cochin Institute,
Paris, France) [49].
Viral plasmids used to create pseudovirus, including HIV-1 PVO clone 4 (SVPB11), ZM53M.PB12
(SVPC11), and pSG3∆env, were obtained from the AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, National Institutes of Health; PVO, clone 4 (SVPB11) was from David
Int. J. Mol. Sci. 2017, 18, 1575 11 of 15
Montefiori and Feng Gao [50]; ZM53M.PB12, SVPC11 was from Cynthia A. Derdeyn and Eric
Hunter [51]; plasmid pSG3∆env was obtained from John C. Kappes and Xiaoyun Wu [51–53].
4.6. Single Round Pseudovirus Production
293FT cells were co-transfected with the pSG3∆env plasmid and an envelope plasmid using the
XTreme Gene Transfection Reagent (Roche/Sigma-Aldrich, St. Louis, MO, USA). 48 h post-transfection,
the supernatant was collected, centrifuged, and filtered with a 0.45-µm syringe filter. The viral stocks
were then stored at −80 ◦C.
4.7. Single-Round Pseudoviral Assay
HeLa-TZM-bl cells were grown in culture media (10% Fetal Bovine Serum (FBS),
penicillin/streptomycin, 25 mM HEPES in Dulbecco’s Modified Eagle’s Medium (DMEM)).
104 cells per well were seeded into a 96-well plate and allowed to incubate at 37 ◦C overnight.
Media was then aspirated and replaced with 50 µL fresh media and allowed to incubate for 2 h.
For preparation of inhibitor, a deep-well dish was made with varying concentrations of inhibitor
diluted into phosphate-buffered saline (PBS) and mixed thoroughly. 20 µL of inhibitor from these
dilutions (or 20 µL PBS for controls) were added to the TZM cell-containing wells, and the plate was
rotated for 1 min to mix, before incubating for 30 min at 37 ◦C. 30 µL of single-round virus (described
above) in media was then added (with non-viral media to the negative control) for a final volume of
100 µL/well and the plate was rotated for 1 min to mix. This “layering” method differs from other
similar pseudoviral assays, where the inhibitor is mixed in-well. In our hands, mixing in-well leads to
lower IC50 (apparent better inhibition), but current experiments use “layering” addition to more closely
mimic conditions under which a topical microbicide may be used. After 20 h, media was aspirated and
replaced with 100 µL/well of fresh media. After 48 more hours, the media was aspirated and the cells
were lysed using 30 µL/well of 0.5% NP-40 in PBS. Lysed cells were incubated at room temperature
for 25 min. Substrate was added (30 µL/well; 8 mM chlorophenol red-β-D-galactopyranoside, 10 mM
β mercaptoethanol, 20 mM KCl in PBS). The absorbance signals at wavelengths 570 and 630 nm were
measured, and the 570:630 ratio for each well was calculated. All inhibitors were tested in triplicate
repeated three times. The data were plotted using Microsoft Excel, and the IC50 value was determined
using a linear equation fitted between two data points surrounding 50% inhibition.
4.8. CCR5 Functional Assays in CHO-K1 Cells
The functional response of CCR5-expressing cells to RANTES and its variants was analyzed by
measuring the luminescence of aequorin in response to release of Ca2+ as described previously [54].
Briefly, CHO-K1 cells were cultured in Ham’s F12 medium (Corning, Cellgro, Manassas, VA, USA)
supplemented with 10% FBS (Life Technologies, Carlsbad, CA, USA), 100 units/mL penicillin,
100 µg/mL streptomycin, and 400 µg/mL G418 (Life technologies, Carlsbad, CA, USA), then removed
from plates by incubating at 37 ◦C with versene (Gibco, Gaithersburg, MD, USA), and then adding 3×
volume Ca2+- and Mg2+-free DMEM (GE Healthcare, Little Chalfont, UK) to gently resuspend. The
cells were gently pelleted for 4 min at 600× g and then resuspended at a density of 5 × 106 cells/mL
using Ham’s F12 Medium supplemented with 10% FBS, penicillin/streptomycin, 25 mM HEPES.
Cells were then incubated in the dark at room temperature, for 1 h with 5 µM coelenterazine H
(Promega, Madison, WI, USA). Cells were then diluted five-fold using Ham’s F-12 medium, and 50 µL
(50,000 cells) were added per well in a 96-well plate. 50 µL of each inhibitor diluted in Ham’s F-12
medium were added to each well at varying concentrations. Luminescence was measured in 30 s
increments using an Orion II microplate luminometer (Berthold Techniques, Bad Wildbad , Germany).
4.9. CCR5 Activity in HeLa-P5L
The functional response of CCR5-expressing cells HeLa-P5L to RANTES and its variants was
analyzed by measuring the fluorescence using Fluo-4 dye (Thermo Scientific, Waltham, MA, USA)
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according to the manufacturer’s suggested protocol. Briefly, HeLa-P5L cells were cultured in
RPMI-1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS, and 100 units of penicillin
and 0.1 mg/mL streptomycin. The expression of CCR5 was selectively expressed by adding zeocin
(Invitrogen, Carlsbad, CA, USA) at 0.5 mg/mL. Cells were then removed from plates by incubating
at 37 ◦C with versene solution (Gibco, Gaithersburg, MD, USA) and then gently resuspended with
culture media. The cells were gently pelleted for 4 min at 600× g and then resuspended at a density of
1 × 106 cells/mL and 100 µL was plated onto 96 well plates with black polystyrene wells and a flat,
micro-clear bottom (Greiner CELLSTAR). After a 15 h incubation at 37 ◦C, wells were washed three
times with sterile Hank’s buffered salt solution (HBSS), 137 mM NaCl, 5.4 mM KCl, 0.25 mM Na2HPO4,
0.44 mM KH2PO4, 1.3 mM CaCl2, 1.0 mM MgSO4, 1.0 mM MgCl2, 10 mM glucose, 10 mM HEPES, with
pH adjusted to 7.4 using 1N NaOH. 50 µL of 2 µM Fluo-4-AM Ester (Invitrogen, Carlsbad, CA, USA)
in HBSS was added. The plate was incubated in the dark at room temperature for 30 min, then washed
three times with HBSS supplemented with 2 mM Probenecid (Tocris, Bristol, UK), then left to incubate
with 80 µL/well of HBSS with 2 mM Probenecid for 30 min at 37 ◦C. Fluorescence was measured after
addition of 20 µL of chemokine variants in HBSS for a final chemokine concentration of 300 nM/well.
Fluorescence reading was done on a Cytation 5 Cell Imaging Multi-Mode Reader (Biotek, Winooski,
VT, USA) with an absorption/emission at 494/516 nm at 35 s, with wild type RANTES/CCL5 as a
positive control and HBSS containing no inhibitor as a negative control.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/7/1575/s1.
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Abbreviations
HIV Human Immunodeficiency Virus
AIDS Acquired Immune Deficiency Syndrome
CCL5 Chemokine (C-C Motif) Ligand 5; also called RANTES
RANTES Regulated on Activation, Normal T-cell Expressed and Secreted; also called CCL5
Gln/Q Glutamine
Glu/E Glutamate
Asn/N Asparagine
Phe/F Phenylalanine
Ile/I Isoleucine
DMEM Dulbecco’s Modified Eagle’s Medium
NMR Nuclear Magnetic Resonance
HBSS Hank’s Buffered Salt Solution
FBS Fetal Bovine Serum
HSQC Heteronuclear Single Quantum Coherence
CHO Chinese Hamster Ovary
IPTG Isopropyl β-D-1-thiogalactopyranoside
TFA Trifluoroacetic Acid
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